Status:
WITHDRAWN
The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
Lead Sponsor:
University of Nebraska
Collaborating Sponsors:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
19-65 years
Phase:
PHASE4
Brief Summary
Participants with multiple sclerosis that are currently treated with glatiramer acetate (GA, Copaxone®) injections and have redness, pain, swelling, itching or a lump at the injection site will be rec...
Detailed Description
Participants are asked to be in this study because they have multiple sclerosis, are currently treated with glatiramer acetate (GA, Copaxone®) injections and have redness, pain, swelling, itching or a...
Eligibility Criteria
Inclusion
- Able to give informed consent
- Between ages 19-65
- Laboratory supported diagnosis of multiple sclerosis
- Currently treated with injectable GA, experiencing wheal and flare after injection
Exclusion
- Unable to give informed consent
- Treated with any other therapy for Multiple Sclerosis
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00988988
Start Date
February 1 2010
End Date
August 3 2012
Last Update
August 23 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.